You are here

MSC Trends and Dosing in Clinical Trials

A new study from the lab of Martin Grumet (Rutgers University, Piscataway, NJ, USA) assessed clinical trials using mesenchymal stem cells (MSCs) to search for potential factors that may influence the design of new trials. Now, Kabat et al. report the requirement for critical cell doses for the most effective stem cell therapies given via for intravenous injection, the method used in almost half of all therapies. While increasing doses are usually tested for safety, and the highest tolerated dose is often used in a clinical trial, future studies may need to measure initial efficacy along with safety to use the most effective doses rather than the safest doses tolerated. For all the fascinating details, see STEM CELLS Translational Medicine now!